Monday, March 18, 2013
Japanese pharmaceutical companies have historically been
thought of as stodgy, insular and opaque, but that is changing fast. One year
into the job, Kyowa
Hakko Kirin Co. Ltd.'s CEO is building his company along lines that
would sound familiar to any Western biopharma CEO: growing organically by
combining the company's technology - much of which he helped discover - with
targets out of academia.
Nobuo Hanai became president
and CEO last March. To compete in today's environment, his senior management
has concluded KHK must transform itself from a Japan-centric company into a
global specialty pharmaceutical player.